Atrial fibrillation
Conditions
Interventions
Case series:Cryoablation
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 75 years old; 2) Patients with paroxysmal atrial fibrillation with symptoms; 3) Those with symptomatic atrial fibrillation who have taken at least one type I or III antiarrhythmic drug treatment effect or cannot tolerate drug treatment; 4) Able to understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Echocardiography shows that the anteroposterior diameter of the left atrium >=50 mm; 2) Preoperative CT or esophageal echocardiography revealed thrombosis in the left atrium/left atrial appendage; 3) Those who have received left atrial ablation or left atrial surgery; 4) Those who have undergone left atrial appendage occlusion or are planning to undergo one-stop atrial fibrillation ablation and left atrial appendage occlusion; 5) New York Heart Function Classification (NYHA) grade III or IV congestive heart failure or LVEF (%) less than 40%; 6) Those who have undergone valve repair; 7) Patients with typical atrial flutter or other supraventricular tachycardia (duration greater than 30 s) confirmed by ECG or Holter before operation; 8) Secondary atrial fibrillation, including ineffective control of hyperthyroidism, acute alcoholism, atrial fibrillation after cardiac surgery, etc.; 9) A history of acute coronary events or a history of percutaneous coronary stent intervention within 6 months before enrollment; 10) Those who have a history of cardioverter defibrillator (ICD) implantation or cardiac resynchronization therapy (CRT); 11) A history of stroke or transient ischemic attack within 6 months before enrollment; 12) Those who have obvious bleeding tendency and cannot accept postoperative systemic anticoagulation; 13) Severe organic heart disease, including moderate to severe mitral regurgitation or stenosis, previous myocardial infarction, hypertrophic cardiomyopathy, etc.; 14) Combined with other serious diseases, life expectancy is less than 12 months; 15) Women who are pregnant, breastfeeding and preparing to become pregnant; 16) Those who have participated or are participating in clinical research of other drugs or devices within 3 months before enrollment; 17) Other conditions assessed by the investigator that are not suitable for inclusion in this study, such as mental or psychological disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-lead ECG;Holter;Transesophageal ultrasonography;Echocardiography;Major organ bleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| International normalized ratio;Left ventricular ejection fraction;New York Heart Association; | — |
Countries
China
Contacts
Public ContactYawei Xu
Shanghai Tenth People's Hospital
Outcome results
None listed